-

Blue Matter Hires New Partner, Eva Kersey, Further Strengthening Capabilities in Europe

LONDON--(BUSINESS WIRE)--Blue Matter is pleased to announce that Eva Kersey has joined the firm as a Partner based in London. Eva officially joined the Blue Matter team on September 16, bringing a broad base of strategic consulting experience across pharmaceutical, biotech, and medical technology clients.

Eva has been serving life science clients since 2007. She began her consulting career at PHP (now a part of Accenture). Since then, she has served in leadership and Partner-level positions at IMS Consulting, IQVIA, and ClearView Healthcare Partners. Over the years, her consulting experience has spanned the full value chain, focusing on cross-functional strategy development. She brings a particular specialization in therapy and franchise strategy, portfolio optimization, and pricing, access and evidence strategy. She also brings significant expertise in all aspects of commercial strategy development for clinical-stage, pre-launch assets.

“I’m extremely excited to join the Blue Matter team,” Eva said. “The firm offers a rare combination of creative thinking and analytical rigor, which is often hard to find. The open, engaging, and collaborative culture is also very attractive to me.”

Blue Matter Managing Partner, George Schmidt, said, “We are thrilled to have Eva on board. Her leadership values—including leading with purpose and trust, inspiring through action, and putting people first—are a perfect fit for our culture. We are confident that her strategic vision will be a multiplier in Blue Matter's growth narrative, particularly in Europe.”

Eva’s educational background includes MBA from the University of Bayreuth, an MA in International Marketing from the University of Nottingham, and a BSc in Business Administration and Economics from TU Bergakademie Freiberg.

About Blue Matter

Blue Matter (www.bluematterconsulting.com) is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels with a focus on corporate and product strategy in complex markets, as well as organizational effectiveness.

Contacts

For more information, contact:
Craig Dunkley
cdunkley@bluematterconsulting.com
(919) 539-0658

Blue Matter



Contacts

For more information, contact:
Craig Dunkley
cdunkley@bluematterconsulting.com
(919) 539-0658

More News From Blue Matter

Blue Matter Expands Capabilities in Healthcare Policy Support for Life Sciences Led by Partner, Milena Sullivan

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025. Milena Sullivan brings more than 20 years of experience in healthcare policy, advocacy, and market access, advising life science companies, trade associations, and provider organizations on policy issues shaping their business. Prior to joining Blue Matter, she spent almost a decade with Avalere H...

AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel

ROTTERDAM, Netherlands--(BUSINESS WIRE)--AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capab...

Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity - from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign. The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut ac...
Back to Newsroom